Support for TAKING VITRAKVI®

You’re not in this alone

TRAK Assist, from the makers of VITRAKVI, provides you with a single point of contact for a range of support services and resources to:

  • Offer a dedicated phone line providing patients taking VITRAKVI with direct access to a nurse or pharmacist who can answer treatment questions
  • Help you understand your insurance benefits for VITRAKVI
  • Assist with overcoming barriers to insurance coverage
  • Connect you with co-pay assistance if you are eligible
    • Including the TRAK Assist $0 Co-Pay Program for VITRAKVI, available if you have commercial insurance*
  • Aid in researching alternative co-pay or support options
  • Help you, through the Bayer US Patient Assistance Foundation, if you do not have insurance or your insurance does not cover your prescription

To learn more about support through TRAK Assist, call 1-844-634-8725.

*Patients who are enrolled in any type of government insurance or reimbursement programs are not eligible. As a condition precedent of the co-payment support provided under this program, e.g., co-pay refunds, participating patients and pharmacies are obligated to inform insurance companies and third-party payors of any benefits they receive and the value of this program, as required by contract or otherwise. Void where prohibited by law, taxed, or restricted. Patients enrolled in the Bayer US Patient Assistance Foundation are not eligible. Bayer may determine eligibility, monitor participation, equitably distribute product and modify or discontinue any aspect of the TRAK Assist program at any time, including but not limited to this commercial co-pay assistance program.


Hear from an actual VITRAKVI patient

Nichol Miller

Nichol Miller was diagnosed with cancer in 2014. Despite going through several rounds of chemotherapy and multiple surgeries, her cancer spread. Not one to give up easily, she and her family traveled 700 miles to the nearest clinical trial site for VITRAKVI after finding out that her cancer is caused by an abnormal TRK protein.

Find out more about Nichol's incredible journey.

You’re not alone. See Nichol’s story.

TRK, tropomyosin receptor kinase.

What is VITRAKVI?

VITRAKVI is a prescription medicine that is used to treat adults and children with solid tumors (cancer) that:

  • are caused by certain abnormal NTRK genes and
  • have spread or if surgery to remove their cancer is likely to cause severe complications, and
  • there is no acceptable treatment option or the cancer grew or spread on other treatment.

Your healthcare provider will perform a test to make sure that VITRAKVI is right for you.

It is not known if VITRAKVI is safe and effective in children younger than 1 month of age.

VITRAKVI is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in other clinical trials.

Important Safety Information

VITRAKVI may cause serious side effects, including:

  • Nervous system problems. Tell your healthcare provider if you develop any symptoms such as confusion, difficulty speaking, dizziness, coordination problems, tingling, numbness, or burning sensation in your hands and feet. Your healthcare provider may temporarily stop treatment, decrease your dose, or permanently stop VITRAKVI if you develop symptoms of a nervous system problem with VITRAKVI.
  • Liver problems. Your healthcare provider will do blood tests to check your liver function during treatment with VITRAKVI. Tell your healthcare provider right away if you develop symptoms of liver problems, including: loss of appetite, nausea or vomiting, or pain on the upper right side of your stomach area. Your healthcare provider may temporarily stop treatment, decrease your dose, or permanently stop VITRAKVI if you develop liver problems with VITRAKVI.

Before starting VITRAKVI, tell your healthcare provider about all of your medical conditions, including if you:

  • have liver problems
  • have nervous system (neurological) problems
  • are pregnant or plan to become pregnant. VITRAKVI can harm your unborn baby. You should not become pregnant during treatment with VITRAKVI.
    • If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with VITRAKVI.
    • Females who are able to become pregnant should use effective birth control (contraception) during treatment and for at least 1 week after the final dose of VITRAKVI. Talk to your healthcare provider about birth control methods that may be right for you.
    • Males with female partners who are able to become pregnant should use effective birth control during treatment with VITRAKVI and for at least 1 week after the final dose of VITRAKVI.
  • are breastfeeding or plan to breastfeed. It is not known if VITRAKVI passes into your breast milk. Do not breastfeed during treatment and for 1 week after the last dose of VITRAKVI.
  • VITRAKVI may affect fertility in females and may affect your ability to become pregnant. Talk to your healthcare provider if this is a concern for you.

While on VITRAKVI, you should avoid:

  • driving or operating machinery until you know how VITRAKVI affects you. VITRAKVI can make you feel dizzy.
  • taking St. John's wort, eating grapefruit, or drinking grapefruit juice during treatment with VITRAKVI.

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter (OTC) medicines, vitamins, and herbal supplements. Certain other medicines may affect how VITRAKVI works.

The most common side effects with VITRAKVI include:

These are not all the possible side effects with VITRAKVI. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

For important risk and use information about VITRAKVI, please see the full Prescribing Information.

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
For Bayer products you can report these directly to Bayer by clicking here.

NTRK, neurotrophic receptor tyrosine kinase.

Attention

You are now leaving the VITRAKVI.com website.
Bayer is not responsible for the content presented by any independent website, including any advertising claims, special offers, illustrations, names, or endorsements.

Thank you for visiting VITRAKVI.com.

Attention

The information provided in this section is intended
expressly for healthcare professionals in the United States.
Click 'OK' to enter if you are a US healthcare professional

Attention

You are now leaving the VITRAKVI.com website.
Bayer is not responsible for the content presented by any independent website, including any advertising claims, special offers, illustrations, names, or endorsements.

Thank you for visiting VITRAKVI.com.

Attention

You are now leaving the VITRAKVI.com website.
Bayer is not responsible for the content presented by any independent website, including any advertising claims, special offers, illustrations, names, or endorsements.

Thank you for visiting VITRAKVI.com.

Attention

You are now leaving the VITRAKVI.com website.
Bayer is not responsible for the content presented by any independent website, including any advertising claims, special offers, illustrations, names, or endorsements.

Thank you for visiting VITRAKVI.com.